Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluated the efficacy and safety of amlodipine/benazepril compared with that of enalapril in the treatment of hypertension in African-American patients with type 2 diabetes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amlodipine/benazepril | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Time from baseline to the achievement of first treatment success (defined as achieving a blood pressure (BP) <130/80 mm Hg). The proportion and cumulative proportion of patients who achieved first treatment success were also determined. |
| Measure | Description | Time Frame |
|---|---|---|
| change from baseline in sitting diastolic BP at Week 24 | ||
| change from baseline in sitting systolic BP at Week 24 | ||
| change from baseline in urinary protein excretion at Week 24 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals Corporation | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | East Hanover | New Jersey | 07936 | United States |
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C044946 | benazepril |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| change from baseline in HbA1c at Week 24 |
| change from baseline in estimated glomerular filtration rate (EGFR) at Week 24 |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |